Bluebird to Present Fresh Data on CAR T-cell Therapy for Myeloma
Bluebird to Present Follow-Up Data for CAR T-cell Therapy in Advanced Numerous Myeloma Patients Patients with advanced numerous myeloma who received three or more lines of therapy have shown promising safety and efficacy results in a Phase one trial assessing bluebird bio’s fresh CAR T-cell therapy bb2121.